Wegovy Availability in the UK Right Now

What NICE and the MHRA have confirmed about Wegovy's status

Wegovy received its UK marketing authorisation and became available to prescribe from 2023. NICE recommended semaglutide for weight management under Technology Appraisal 875, though its NHS recommendation came with strict conditions: use within a specialist weight management service, for a maximum of two years, and only for adults with a BMI of 35 or above (or 30–34.9 in certain circumstances) plus at least one weight-related comorbidity. Lower BMI thresholds (roughly 2.5 kg/m² less) apply for South Asian, Chinese, Middle Eastern, Black African and African-Caribbean backgrounds.

The licensed dosing pathway runs from 0.25mg up to a standard maintenance dose of 2.4mg, titrated over roughly five months by a prescriber. Then, in January 2026, the MHRA approved 7.2mg as a higher maintenance option, initially delivered as three 2.4mg weekly injections. By April 2026, a dedicated single-dose 7.2mg pen had been approved for adults with a BMI of 30 or above. Trials of the 7.2mg dose reported an average weight loss of around 20.7% over 72 weeks, closing the gap with tirzepatide results significantly. Both approvals are documented on GOV.UK.

What this means practically: Wegovy is available, it is licensed, and the dose ceiling has risen. Whether a specific pen format is in stock at a given pharmacy on a given week is a separate question entirely.

Why semaglutide availability has been patchy, and where things stand now

Demand for GLP-1 medicines globally outstripped manufacturing capacity through 2023 and into 2024. Novo Nordisk prioritised certain markets and dose strengths, and the UK saw intermittent shortages, particularly at the mid-range titration doses. By late 2025 and into 2026, the supply picture through regulated UK private pharmacies had improved markedly, though availability still varies by dose and week.

A practical note on timing: orders placed around bank holidays or the end of the month (when a lot of people reorder) can occasionally face a short delay. Ordering mid-week, well before a holiday window, tends to be the smoothest approach. That's a small thing, but it matters when you're mid-titration.

NHS availability is a separate story. Under TA875, semaglutide on the NHS is routed through specialist services with waiting lists that, in many areas, run to months or longer. General practice prescribing of Wegovy under NHS terms is not yet established in the way that tirzepatide's primary-care rollout is now proceeding. For most people looking for semaglutide for weight management today, a private prescription through a GPhC-registered pharmacy is the realistic route.

Counterfeit supply is a genuine risk worth naming directly. The MHRA has warned repeatedly about fake weight-loss injections sold through social media and unverified websites, pens offered without a clinical assessment, at prices far below market. Fake pens have been found to contain insulin and other substances. Any seller offering semaglutide without requiring a prescription is operating illegally, and the product cannot be verified as genuine. Suspect sellers can be reported at the MHRA's Yellow Card scheme.

Who can access Wegovy privately right now

Private eligibility follows the licensed criteria in the Wegovy SmPC: adults aged 18 or over with a BMI of 30 or above, or a BMI of 27 or above alongside a qualifying condition. That list includes type 2 diabetes, pre-diabetes, high blood pressure, raised cholesterol, obstructive sleep apnoea and cardiovascular disease, among others. BMI is one input, a prescriber reviews the full picture, including other medicines, medical history and current health, before approving treatment.

Wegovy is not recommended during pregnancy, while breastfeeding, or if you are actively trying to conceive. It is not licensed for under-18s. Some conditions, including a personal or family history of medullary thyroid cancer or MEN2, require careful prescriber assessment. These are conversations for a clinical consultation, not a checklist.

For a fuller sense of how semaglutide works and what to expect from treatment, that page covers the mechanism, what the evidence shows, and the practical side-effect profile in detail. Some people also want to know whether Wegovy can cause irritability, which is a reasonable question given that mood changes are sometimes reported during significant dietary shifts and weight loss. If cost is the deciding factor in where you access it, the Wegovy price page sets out what private treatment typically costs and what a legitimate price should include.

Wegovy near you: what that actually means

Searches for semaglutide availability near a specific location usually reflect one of two things: someone looking for a local GP or clinic who prescribes it, or someone wanting same-week collection. It is worth being clear about both. NHS prescribing of Wegovy through a GP is not widely available yet, the specialist-service route means most GP practices cannot currently prescribe it under NHS terms. Private clinics vary considerably in how they operate.

Regulated online pharmacies can legally prescribe and dispense Wegovy to any UK address, subject to clinical assessment. There is no geographic restriction. Wegovy near you is, in practice, any GPhC-registered pharmacy that holds stock and has a prescribing pathway, not just one within driving distance. You can verify any online pharmacy on the GPhC register.

At nume, a GPhC-registered Independent Prescriber personally reviews every consultation. Orders placed before 12pm Monday to Friday are dispatched the same day once approved, delivered free by DPD the next working day. More about how we work is on our about page, or you can review your treatment options and start a free consultation if Wegovy looks like the right fit.